|Description||Caracemide is an agent derived from acetohydroxamic acid. It has potential antineoplastic activity. Caracemide can inhibit ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth. But in Feb 1995, Phase II for Cancer in USA was discontinued.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Aventis|
BAY 56-3722, a water-soluble camptothecin derivative, is a DNA-Intercalating drug that stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-d...
Doravirine is a non-nucleoside reverse transcriptase inhibitor under development of Merck & Co. IC 50 value is 12 nM against the wild type, 21nM against K103N, ...
MS-073 is a Type II DNA topoisomerase inhibitor under the development of Nihon Schering. MS-073 can overcome MDR in vitro and in vivo compare to verapamil. MS-0...
CP 115953 is a Type II DNA topoisomerase inhibitor originated by Pfizer. CP 115953 inhibits topoisomerase II activity via an interaction with the enzyme and not...
TH588 selectively kill U2OS and other cancer cell lines with less toxic to several primary or immortalized cells.
BMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
Amenamevir is a DNA helicase-primase inhibitors. It has anti-HSV activity against herpes simplex keratitis. In Mar 2016, Mahuro completed a phase III trial in H...
This active molecular is a DNA-directed DNA polymerase inhibitor potentially originated by Medivir AB. Omaciclovir can be selectively phosphorylated by viral th...
LMI070, also called as NVS-SM1, is a selective, high plasma exposure and orally active modulator of SMN2 splicing which demonstrates robust activity across dise...
The hydrochloride salt form of Tinostamustine, a benzimidazol derivative, has been found to be a HDAC inhibitor and could probably be effective against sorts of...
BRD7116, a bis-aryl sufone with cell-non-autonomous anti-leukemia activity, competitively binds to bacterial DNA gyrase and is an inhibitor of leukemia stem cel...
Caracemide is an agent derived from acetohydroxamic acid. It has potential antineoplastic activity. Caracemide can inhibit ribonuclease reductase, resulting in ...
CP-74667 is a Type II DNA topoisomerase inhibitor originated by Pfizer. No development was reported for Bacterial infections in USA.
Acelarin is a DNA synthesis inhibitor with EC50 of 0.2 nM. Acelarin is a prodrug based on an aryloxy phosphoramidate derivative of gemcitabine. It is converted ...
Oxolinic acid, a potent inhibitor of DNA gyrase and DNA synthesis, can examined Gyrase-chromosome interactions.
Lobucavir is a RNA-directed DNA polymerase inhibitor originated by Bristol-Myers Squibb as a nucleoside analog. Treatment for Cytomegalovirus infections, Hepati...
L67 is a DNA Ligase Inhibitor. L67 inhibited DNA ligases I and III. L67 is a simple competitive inhibitor with respect to nicked DNA. L67 inhibits DNA ligases I...
Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
L189 is a DNA ligase I, III and IV inhibitor (IC50 values are 5, 9 and 5 μM respectively) that blocks DNA binding. L189 inhibits base excision repair (BER) and ...
TH588 hydrochloride, with potent anti-cancer property, is a novel inhibitor that highly selectively targets MTH1 protein (IC50= 5 nM) which is required for canc...